Related Experiment Video
Updated: Mar 30, 2026

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
Frequency of MELAS main mutation in a phenotype-targeted young ischemic stroke patient population
Turgut Tatlisumak1,2,3, Jukka Putaala4, Markus Innilä5
1Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Per Dubbsgatan 14, POB 430, 40530, Gothenburg, Sweden. turgut.tatlisumak@neuro.gu.se.
Abstract:
Mitochondrial diseases, predominantly mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), may occasionally underlie or coincide with ischemic stroke (IS) in young and middle-aged individuals. We searched for undiagnosed patients with MELAS in a target subpopulation of unselected young IS patients enrolled in the Stroke in Young Fabry Patients study (sifap1). Among the 3291 IS patients aged 18-55 years recruited to the sifap1 study at 47 centers across 14 European countries, we identified potential MELAS patients with the following phenotypic features: (a) diagnosed cardiomyopathy or (b) presence of two of the three following findings: migraine, short stature (≤165 cm for males; ≤155 cm for females), and diabetes. Identified patients' blood samples underwent analysis of the common MELAS mutation, m.3243A>G in the MTTL1 gene of mitochondrial DNA. Clinical and cerebral MRI features of the mutation carriers were reviewed. We analyzed blood samples of 238 patients (177 with cardiomyopathy) leading to identification of four previously unrecognized MELAS main mutation carrier-patients. Their clinical and MRI characteristics were within the expectation for common IS patients except for severe hearing loss in one patient and hyperintensity of the pulvinar thalami on T1-weighted MRI in another one. Genetic testing for the m.3243A>G MELAS mutation in young patients with IS based on phenotypes suggestive of mitochondrial disease identifies previously unrecognized carriers of MELAS main mutation, but does not prove MELAS as the putative cause.
Insights
Genetic testing identified previously unrecognized carriers of the main mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) mutation in young ischemic stroke patients. This highlights the importance of considering MELAS in stroke evaluations.
Area of Science:
- Neurology
- Genetics
- Mitochondrial Biology
Background:
- Mitochondrial diseases, particularly MELAS, can be associated with ischemic stroke in younger individuals.
- Identifying these underlying conditions is crucial for accurate diagnosis and management.
Purpose of the Study:
- To investigate the prevalence of undiagnosed MELAS in a cohort of young ischemic stroke patients.
- To identify carriers of the common m.3243A>G MELAS mutation within this population.
Main Methods:
- Phenotypic screening of 3291 young ischemic stroke patients for MELAS suggestive features.
- Genetic analysis of blood samples for the m.3243A>G mutation in identified patients.
- Review of clinical and MRI data of mutation carriers.
Main Results:
- Four previously unrecognized carriers of the MELAS m.3243A>G mutation were identified among 238 analyzed patients.
- Most carriers presented with typical ischemic stroke features, with some exhibiting hearing loss or specific MRI findings.
Conclusions:
- Genetic testing based on suggestive phenotypes can uncover MELAS mutation carriers among young ischemic stroke patients.
- While identifying carriers is important, it does not definitively prove MELAS as the cause of stroke without further clinical correlation.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Related Concept Videos
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Point and Frameshift Mutations